Medizin
Refine
Year of publication
- 2016 (316) (remove)
Document Type
- Article (282)
- Doctoral Thesis (14)
- Part of Periodical (11)
- Book (4)
- Contribution to a Periodical (3)
- Conference Proceeding (1)
- Preprint (1)
Has Fulltext
- yes (316) (remove)
Is part of the Bibliography
- no (316) (remove)
Keywords
- Mitochondria (4)
- apoptosis (4)
- Apoptosis (3)
- Cancer (3)
- HIV (3)
- ROS (3)
- autophagy (3)
- cirrhosis (3)
- ABCB1 (2)
- Aging (2)
- Angiogenesis (2)
- B-cell lymphoma (2)
- Borrelia (2)
- Calcium (2)
- Cell signalling (2)
- Cortex (2)
- CyberKnife robotic radiosurgery (2)
- Diabetes mellitus (2)
- Diagnostic markers (2)
- Exercise (2)
- Experimental models of disease (2)
- Gender (2)
- Heart transplantation (2)
- Immunotherapy (2)
- Infection (2)
- NADPH oxidase (2)
- Pain (2)
- Patient blood management (2)
- Pneumonia (2)
- Proteomics (2)
- Stereotactic body radiation therapy (2)
- Structural plasticity (2)
- VEGF (2)
- atrial fibrillation (2)
- breast cancer (2)
- cancer (2)
- caspase-8 (2)
- complementary and alternative medicine (2)
- development (2)
- diagnosis (2)
- glioblastoma (2)
- hepatitis C (2)
- human (2)
- liver transplantation (2)
- mitosis (2)
- particulate matter (2)
- renal cell carcinoma (2)
- surgery (2)
- ubiquitination (2)
- A/D transition (1)
- ABS (1)
- AGC kinase (1)
- AIH immunopathogenesis (1)
- AJAP1 (1)
- APMPPE - acute posterior multifocal placoid pigment epitheliopathy (1)
- APP (1)
- ARDS (1)
- Abdominal infections (1)
- Academic medicine (1)
- Access (1)
- Acute calcolous cholecystitis (1)
- Acute leukemia (1)
- Acute myeloid leukemia (1)
- Adherence junctions (1)
- Adolescents (1)
- Adverse events (1)
- Air traffic (1)
- All-trans retinoic acid (1)
- Allergic asthma (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Ameloblastoma (1)
- Anaemia (1)
- Anatomy (1)
- Anemia (1)
- Anti platelet therapy (1)
- Anti-tumor immunity (1)
- Antibiotic (1)
- Antibiotic stewardship (1)
- Anticoagulation (1)
- Antimicrobial resistance (1)
- Antivenom (1)
- Arrhythmia/all (1)
- Ascites (1)
- Aspergillus fumigatus (1)
- Atherosclerosis (1)
- Atrial fibrillation (1)
- Atxn2 (1)
- Aurora (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Automatic Environmental Tobacco Smoke Emitter (1)
- Autophagy (1)
- Azan trichrome stain (1)
- B-cell non-Hodgkin lymphoma (1)
- BMC (1)
- Backpropagating action potential (1)
- Bacterial infection (1)
- Bacterial pathogenesis (1)
- Bariatric surgery (1)
- Beatmung (1)
- Becton Dickinson (1)
- Benefit (1)
- Bibliometric analysis (1)
- Biliary tree stones (1)
- Bisphosphonates (1)
- Blood loss (1)
- Blood transfusion (1)
- Bone defect (1)
- Bone regeneration (1)
- Brain injury (1)
- Breast cancer (1)
- Breech delivery (1)
- Bungarus niger (1)
- C. elegans (1)
- CA1 (1)
- CD95/Fas receptor (1)
- CDK inhibitor (1)
- CIK cells (1)
- CNS cancer (1)
- COPD (1)
- CRISPR/Cas9 (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CUELA (1)
- CYBA/p22phox (1)
- CYP1A1 (1)
- Cancer Staging (1)
- Cancer detection (1)
- Capecitabine (1)
- Carbapenem-resistente Gram-negative Bakterien (CRGN) (1)
- Carbapenemasen (1)
- Cardiac (1)
- Cardiac output (1)
- Cardiology (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Catch-up validation study (1)
- Catheter ablation (1)
- Cats (1)
- Cdk1/cyclin B1 (1)
- Celiac disease (1)
- Cell salvage (1)
- Cell therapy (1)
- Cerebellum (1)
- Cerebral cortex (1)
- Cesarean delivery (1)
- Checkpoint inhibitor (1)
- Chemical modification (1)
- Chemiluminescence (1)
- Chemorefractory advanced gastric cancer (1)
- Chemotherapy (1)
- Children (1)
- Chimerism (1)
- Cholecystectomy (1)
- Chondral Lesion (1)
- Chorion (1)
- Chronic hepatitis (1)
- Chronic inflammation (1)
- Cigarettes (1)
- Claudin 5 (1)
- Clinical competence (1)
- Clinical genetics (1)
- Clinical skills (1)
- Clinical trial (1)
- Clinical trials (1)
- Clonidine (1)
- Clustering (1)
- Cofilin (1)
- Collagen antibody-induced arthritis (1)
- Comorbidities (1)
- Compartmental modeling (1)
- Complementary medicine (1)
- Complex I (1)
- Compliance (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer simulation (1)
- Conduct disorder (1)
- Congenital ocular motor apraxia (1)
- Conventional Chemotherapeutic (1)
- Cord blood transplantation (1)
- Costs (1)
- Couch tracking (1)
- Craniomandibular disorders (1)
- Critical haematocrit (1)
- Croatia (1)
- Cross-contamination (1)
- Cryo-electron microscopy (1)
- Cryoballoon (1)
- Cytotoxic CD8+ T cell (1)
- DKK1 (1)
- DNA damage (1)
- DNA methylation (1)
- DNA replication (1)
- DNA-protein crosslinks (1)
- Daptomycin (1)
- Databases (1)
- Decision making (1)
- Decision trees (1)
- Decision-making (1)
- Decolonization (1)
- Delegation (1)
- Delivery mode (1)
- Delivery quality assurance (1)
- Dendritic spines (1)
- Denosumab (1)
- Density equalizing (1)
- Density equalizing mapping (1)
- Dentistry (1)
- Desinfektion von Flugzeugen (1)
- Desmin (1)
- Diagnosis (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Disinfection of aircraft (1)
- Distribution (1)
- Dogs (1)
- Domestic (1)
- Drug targeting (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dvc1 (1)
- E-learning (1)
- E. coli (1)
- EQ (1)
- EQ-5D (1)
- ET (1)
- Early goal-directed therapy (1)
- Echocardiography (1)
- Eclampsia (1)
- Economic evaluation (1)
- Economic impact (1)
- Electron transport chain (1)
- Electrotonic analysis (1)
- Elimination (1)
- Emotion regulation (1)
- Emphysema (1)
- Employment effect (1)
- Endometriosis (1)
- Endoscopic ultrasound (1)
- Endothelial permeability (1)
- Entorhinal cortex lesion (1)
- EnvZ signalling (1)
- Envenomation (1)
- Epidermolysis bullosa simplex with muscular dystrophy (1)
- Eradication (1)
- Erythema migrans (1)
- Erythrocytes (1)
- Europe (1)
- Evaluation (1)
- Everolimus (1)
- Evidence-based medicine (1)
- Ewing sarcoma (1)
- Excitability (1)
- Exercise Metabolism (1)
- Extracellular RNA (eRNA) (1)
- FOLFIRI (1)
- Fc receptor (1)
- Feedback (1)
- Females (1)
- Fetal bovine serum (1)
- Fibrosis (1)
- First-line combination antiretroviral therapy (1)
- Fleas (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Folic acid (1)
- Follow-up (1)
- Functional capacity (1)
- Functional clustering (1)
- GSK2334470 (1)
- GVHD (1)
- Gallbladder percutaneous drainage (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gastrointestinal neoplasm (1)
- Gender analysis (1)
- Gene expression (1)
- General clinical cardiology (1)
- General practice/family medicine (1)
- Genetics research (1)
- Germany (1)
- Gestational diabetes (1)
- Gimbaled tracking (1)
- Gram-positive infection (1)
- Granule cell (1)
- Gross tumor volume optimization (1)
- Growth cone (1)
- Guideline (1)
- Guidelines (1)
- H3 receptor (1)
- HMA (1)
- Hausarztpraxis (1)
- Health care workers (1)
- Heart regeneration (1)
- Hemodilution (1)
- Hemodynamic management (1)
- Hemostasis (1)
- Hepatitis C virus (1)
- Hepatitis c (1)
- Herd immunity (1)
- High-dose chemotherapy (1)
- Highly infectious diseases (1)
- Hochansteckende Krankheiten (1)
- Hodgkin lymphoma (1)
- Hodgkin-Lymphom (1)
- Homeostasis (1)
- Homeostatic plasticity (1)
- Homocysteine (1)
- Hospital (1)
- Hospitals (1)
- Household contacts (1)
- Hrvaška (1)
- Human behaviour (1)
- Human physiology (1)
- Humans (1)
- IAP proteins (1)
- IGRA (1)
- IL-11 (1)
- IL-13 (1)
- IL-22 (1)
- IL-6 (1)
- Immobilization (1)
- Immune response (1)
- Immunity (1)
- Immunocompromised (1)
- Immunology and Microbiology Section (1)
- Immunosuppressive agents (1)
- Immunosuppressive therapy (1)
- In vitro (1)
- In vivo (1)
- Incidence (1)
- Individualized intervention (1)
- Indoor air pollution (1)
- Induced pluripotent stem cells (1)
- Infant (1)
- Inflow obstruction (1)
- Influenza (1)
- Intensive care (1)
- Intensive care unit (1)
- Interdisciplinarity (1)
- Intermediate filaments (1)
- Intratumoral (1)
- Iron deficiency anemia (1)
- Ischemia/reperfusion injury (1)
- Ischemia–reperfusion injury (1)
- Itpr1 (1)
- Jaw (1)
- Joint destruction (1)
- Joubert syndrome (1)
- Kidney transplantation (1)
- Kiefer (1)
- Kim-1 (1)
- Kinases (1)
- Kinematic posture analysis (1)
- Krait (1)
- Kraniomandibuläre Dysfunktion (1)
- LC3B (1)
- LDL-cholesterol (1)
- LOS (1)
- LTBI (1)
- Lactation (1)
- Learning outcomes (1)
- Lecture (1)
- Left ventricular assist device (1)
- Left ventricular non-compaction, (1)
- Lenalidomide (1)
- Length of stay (1)
- Lice (1)
- Lineage tracing (1)
- Lipid metabolism (1)
- Lipid signaling (1)
- Lipid signalling (1)
- Liquid filled MicroLion ion chamber array (1)
- Liver cirrhosis (1)
- Liver metastases (1)
- Long-term care (1)
- Longitudinal (1)
- Low back pain (1)
- Ltbp4 (1)
- Lucigenin (1)
- Luftverkehr (1)
- Lungenkontusion (1)
- Lyme borreliosis (1)
- Lyme disease (1)
- Lyme disease - Borreliosis (1)
- MEDIC (1)
- MLC tracking (1)
- MLL-rearranged leukemia (1)
- MMF (1)
- MPA (1)
- MPN (1)
- MPN-U (1)
- MR-based histology (1)
- MRI (1)
- MRSA (1)
- Machine-learning (1)
- Macrophage Transdifferentiation (1)
- Magnetic resonance (1)
- Major bleeding (1)
- Major infection after cardiac surgery (1)
- Mammary gland (1)
- Manufacturing (1)
- Mapping (1)
- Measles (1)
- Medizinische Fachangestellte (1)
- Meldepflicht (1)
- Membrane assays (1)
- Mental health (1)
- Mesenchymal stem/stromal cells (1)
- Metabolic diseases (1)
- Metastatic breast cancer (1)
- Methicillin resistance (1)
- MicroRNAs (miRNAs) (1)
- Migrants (1)
- Minimal residual disease (1)
- Mitochondrial complex I (1)
- Modified FDI criteria (1)
- Molar tooth sign (1)
- Molecular biology (1)
- Monacolin K (1)
- Morphological modeling (1)
- Mortality (1)
- Motor control (1)
- Multi-resistant pathogens (1)
- Multidetector Computed Tomography (1)
- Multimodal imaging (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscarinic acetylcholine receptor (1)
- Muscular diseases (1)
- Musculoskeletal system (1)
- Muskuloskeletales System (1)
- NADH:ubiquinone oxidoreductase (1)
- NHE (1)
- NK cell (1)
- NK cell subset (1)
- NO (1)
- NS3 protease inhibitor (1)
- NSF (1)
- NXF1 (1)
- Nackenmuskulatur (1)
- Neck muscles (1)
- Neoplasms (1)
- Nerve regeneration (1)
- Nervous system diseases (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neurotoxicity (1)
- Nitric oxide (1)
- Non-RCT (1)
- Non-alcoholic fatty liver disease (1)
- Non-coding RNAs (1)
- Non-neuronal cholinergic system (1)
- Nonsteroidal anti-inflammatory drugs (1)
- Nox (1)
- Nox4 (1)
- Nrf2 (1)
- Nucleophosmin-1 (1)
- OECD performance standards (1)
- OPRM1 methylation (1)
- OSCE (1)
- Olfactory system (1)
- Oncolytic adenovirus (1)
- Open source concept (1)
- Oppositional defiant disorder (1)
- Organ motion (1)
- Osmosensing (1)
- Osteoporosis (1)
- Ovarian cancer (1)
- Oxygen consumption (1)
- PAR (1)
- PDK1 (1)
- PELICAN (1)
- PIF pocket (1)
- PMF (1)
- PV (1)
- Parainfluenza (1)
- Parkinson's disease (1)
- Particulate matter (1)
- Patellofemoral Joint (1)
- Pathogen reduction (1)
- Pdgfrβ (1)
- Peer-feedback (1)
- Peer-teaching (1)
- Pegylated liposomal doxorubicin (1)
- Persistence (1)
- Pharmacological treatment (1)
- Pharmacology (1)
- Phosphorylation (1)
- Physicians (1)
- Placental growth factor (1)
- Platelet (1)
- Platelet lysate (1)
- Platelet releasate (1)
- Plectin (1)
- Plk1 inhibitors (1)
- Polo-like kinase 3 (1)
- Polyhexanide (1)
- Population-based screening (1)
- Porin regulation (1)
- Post-translational modifications (1)
- Pre-economic effects (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- Preclinical research (1)
- Predictive medicine (1)
- Preeclampsia (1)
- Pregnancy (1)
- Primary care (1)
- Primärversorgung (1)
- Produkte zur Desinfektion (1)
- Progranulin (1)
- Protein aggregates (1)
- Proximal humeral fracture (1)
- Pseudo HE-images (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Qualifikation (1)
- Quality of care (1)
- Quantitative MRI (1)
- RCT (1)
- RIPK3 (1)
- ROS generation (1)
- RT-qPCR (1)
- Radiofrequency (1)
- Raman spectroscopy (1)
- Randomised controlled trial (1)
- Randomized controlled trial (1)
- Rational use (1)
- Reactive oxygen species (1)
- Recall rate (1)
- Reconstructed human epidermis (1)
- Red blood cells (1)
- Red yeast rice (1)
- Redox (1)
- Regression analysis (1)
- Rehospitalization (1)
- Relapse (1)
- Relaxometry (1)
- Remote ischemic conditioning (1)
- Renal cell carcinoma (1)
- Renal function (1)
- Research architecture (1)
- Residential care (1)
- Resin composites (1)
- Respiration (1)
- Respiratory signs and symptoms (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Robotic tracking (1)
- Roma women (1)
- Rora (1)
- Rotorest (1)
- Ruijs-Aalfs syndrome (1)
- Ryanodine (1)
- S. cerevisiae (1)
- SAP (1)
- SCT (1)
- SPARTAN (1)
- SPRTN (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- STAT3 (1)
- STIR (1)
- SW480 Cell (1)
- Salmonella infection (1)
- Schmerz (1)
- Science structure (1)
- Scientometric analysis (1)
- Scientometrics (1)
- Sclerostin (1)
- Second stage of labor (1)
- Second-line treatment (1)
- Sensorimotor training (1)
- Sensory neuron (1)
- Sepsis-bundle (1)
- Sequence (1)
- Signaling (1)
- Signaling ROS (1)
- Skeletal muscle (1)
- Skeletal muscle fiber-type switching (1)
- Skills training (1)
- Skin irritation test (1)
- Skin manifestation (1)
- Smac (1)
- Smooth muscle cell (1)
- Snakebite (1)
- Socioeconomic status (1)
- Software tool (1)
- Spectral library (1)
- Sphere Formation Assay (1)
- Splice variants (1)
- Standardized operating procedures (1)
- Standardverfahren (1)
- Stroke (1)
- Stroke prevention (1)
- Stroke volume variation (1)
- Substances for disinfection (1)
- Sulfhydryl-reactivity (1)
- Sulfur metabolism (1)
- Sunitinib (1)
- Superinfection (1)
- Superoxide (1)
- Surgery (1)
- Surgical risk (1)
- Surveillance (1)
- Sympathicolysis (1)
- Synaptic plasticity (1)
- Synaptopodin (1)
- Synovial inflammation (1)
- Systematic review (1)
- Systemic treatment (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- T cells (1)
- T1 (1)
- T84 colon carcinoma cells (1)
- TAX1BP1 (1)
- TRAIL (1)
- Target identification (1)
- Targeted therapy (1)
- Tax effect (1)
- Tgfβ (1)
- Therapeutics (1)
- Thermodilution (1)
- Thermoplasma (1)
- Thiol redox modification (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombosis/hypercoagulable states (1)
- Ticks (1)
- Topoisomerase (1)
- Transfusion (1)
- Translational research (1)
- Transmembrane communication (1)
- Transmission (1)
- Trauma (1)
- Travellers (1)
- Treatment (1)
- Treatment protocol (1)
- Tumor suppressor protein (1)
- Tumorsphere Formation (1)
- Tyrosine kinase inhibitor (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- Tyrosine kinases (1)
- USP9X (1)
- Undergraduate training (1)
- Upper respiratory tract infection (1)
- Urban (1)
- VE-cadherin (1)
- Vaccination (1)
- Vaginal breech delivery (1)
- Vaginal delivery (1)
- Value-added effect (1)
- Vascular permeability (1)
- Viral load (1)
- Virological failure (1)
- Voltage attenuation (1)
- WRNIP1 (1)
- XIAP (1)
- Zoonosis (1)
- acetaminophen (1)
- acute coronary syndrome (1)
- acute liver injury (1)
- acute myeloid leukemia (AML) (1)
- adalimumab (1)
- adenomatous polyposis (1)
- adenosine (1)
- adhesion (1)
- adipose tissue-derived stem cell (1)
- advance directive (1)
- advanced care planning (1)
- age-related macular degeneration (1)
- aging (1)
- allogeneic stem cell transplantation (1)
- allosteric regulation (1)
- alternative 3′ end processing (1)
- anal carcinoma (1)
- angiogenesis (1)
- angioplasty (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- animal host (1)
- animal models (1)
- antenatal characteristics (1)
- antenatalne značilnosti (1)
- anti-citrullinated protein antibodies (1)
- anticoagulants (1)
- anticonvulsant activity (1)
- antiviral (1)
- antiviral therapy (1)
- archaea (1)
- archaeosomes (1)
- artery (1)
- astrocytoma (1)
- asymmetric hearing (1)
- auditory development (1)
- autoantibodies (1)
- automatic environmental tobacco smoke emitter (1)
- behavior (1)
- binaural cochlear implants (1)
- bio-absorbable mesh (1)
- biochemistry (1)
- biological mesh (1)
- biomarker (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- brain metastases (1)
- brain states (1)
- brainmass (1)
- brainsize (1)
- bronchial allergen challenge (1)
- burden of illness (1)
- c1orf124 (1)
- cancer care (1)
- cancer care providers (1)
- cancer screening (1)
- candidate genes (1)
- carbapenem-resistant Gram-negative bacteria (CRGN) (1)
- carbapenemases (1)
- carboxyfluorescein (1)
- cardiovascular magnetic resonance (1)
- carotid (1)
- catheterization/diagnostic interventional (1)
- cell biology (1)
- cell death (1)
- cell transplantation (1)
- cells (1)
- central nervous system infection (1)
- chemokines: CYP2D6 model (1)
- chemoradiotherapy (1)
- chromosome segregation (1)
- chronic hepatitis C (1)
- chronic viral hepatitis (1)
- cigarette smoke (1)
- clusteranalysis (1)
- cochlear implant (1)
- cold tolerance (1)
- compaction (1)
- complement (1)
- compliance (1)
- connectional fingerprint (1)
- connective tissue (1)
- continuing education (1)
- cortical layers and areas (1)
- cross-modal plasticity (1)
- cytokine (1)
- cytokines (1)
- deaf white cat (1)
- deafness (1)
- decision making (1)
- dedifferentiation (1)
- dentate gyrus (1)
- dentist (1)
- depression (1)
- deprivation (1)
- desensitization (1)
- desmoplastic stroma (1)
- diclofenac (1)
- differentiation (1)
- diffuse large B cell lymphoma (1)
- diffusion MRI (1)
- diffusion tensor imaging (1)
- direct antiviral agents (1)
- drug resistance (1)
- eNOS (1)
- editorials (1)
- electrocardiography (1)
- endothelial (1)
- endothelial cells (1)
- endothelial receptor expression (1)
- environmental tobacco smoke (1)
- epilepsy (1)
- erosions (1)
- eutheria (1)
- exercise testing (1)
- exome sequencing (1)
- familial colorectal cancer (1)
- fasting (1)
- fear conditioning (1)
- fear generalization (1)
- fibrosarcoma (1)
- fracture (1)
- freeze avoidance (1)
- gadobutrol (1)
- gender (1)
- gene expression (1)
- gene expression profiling (1)
- gene expression profiling (GEP) (1)
- generic preparedness (1)
- glucocorticoids (1)
- gold nanoparticles (1)
- governance (1)
- graph theory (1)
- green fluorescent protein (1)
- guideline (1)
- health-related quality of life (1)
- hepatitis c (1)
- hepatocytes (1)
- hepatotoxicity (1)
- herb induced liver injury (HILI) (1)
- herbal drug (1)
- herbal hepatotoxicity (1)
- hereditary angioedema (1)
- hereditary tumor syndromes (1)
- high-dose chemotherapy (1)
- histamine (1)
- histological validation (1)
- homoarginine (1)
- hormones (1)
- host response (1)
- human brain (1)
- human gingival fibroblasts (1)
- human natural killer cell (1)
- hypoxia (1)
- iCLIP (1)
- immune evasion (1)
- immune reconstitution (1)
- immune response (1)
- immunocompromised patient (1)
- immunologic (1)
- immunostaining (1)
- in situ hybridization (1)
- in situ vaccine (1)
- incisional hernia (1)
- influenza pandemic (1)
- information needs (1)
- innate immunity (1)
- insertable cardiac monitor (1)
- interaural time difference (1)
- interferon (1)
- interferon-free antiviral treatment (1)
- invasion (1)
- irritable bowel syndrome (1)
- isomeric antagonists (1)
- kinase regulation (1)
- kinetische Therapie (1)
- laser (1)
- laser based cell manipulation (1)
- laser microdissection (1)
- leukocytes (1)
- life span (1)
- liposomes (1)
- living will (1)
- local control (1)
- low-dose imaging (1)
- lymphoma pathogenesis (1)
- l‐arginine:glycine amidinotransferase (1)
- mRNA export (1)
- macrophages (1)
- magnetic resonance imaging (1)
- mammals (1)
- management (1)
- mandatory reporting system (1)
- mantle cell lymphoma (1)
- massive parallel sequencing (1)
- maturation (1)
- medical history (1)
- menthol (1)
- men’s (1)
- meta-analysis (1)
- metabolism (1)
- metalloprotease (1)
- miRNA (1)
- microbiome (1)
- microwave ablation (1)
- mismatch repair (1)
- mitotic arrest (1)
- molecular dynamics (1)
- mouse (1)
- multi-drug resistance (1)
- multidrug-resistant Gram-negative bacteria (MRGN) (1)
- multiresistente Gram-negativen Stäbchenbakterien (MRGN) (1)
- neuroblastoma (1)
- neuroinformatics (1)
- neuromodulation (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- noise intervention measures (1)
- nonnucleoside polymerase inhibitor (1)
- non‑Hodgkin's lymphoma (1)
- nuclear hormone receptor (1)
- nursery schools (1)
- observational study (1)
- occupational health (1)
- occupational stress (1)
- oncology (1)
- oral enzyme combination (1)
- orthodontist (1)
- osteoarthritis (1)
- osteoporosis (1)
- osteoporosis treatment (1)
- oval split ring resonator (1)
- p21 phosphorylation (1)
- p21 stability (1)
- pandemic preparedness (1)
- patient’s desires (1)
- pattern (1)
- perforin (1)
- perfusion (1)
- perinatal HIV infection (1)
- periodontal diseases (1)
- periodontitis (1)
- peripheral blood stem cell transplant (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- pixantrone (1)
- pol g (1)
- pollen allergy (1)
- polo-like kinase (1)
- polycystic kidney (1)
- post hoc study (1)
- prefrontal cortex (1)
- prevention (1)
- progenitor (1)
- progeria (1)
- prognosis (1)
- proliferation (1)
- prophylaxis (1)
- protein kinase (1)
- proximal tubule (1)
- psoriatic arthritis (1)
- public health. (1)
- radiological (1)
- randomized controlled trial (1)
- rat model (1)
- real-world data (1)
- renal impairment (1)
- retuximab (1)
- risk communication (1)
- rituximab (1)
- romske ženske (1)
- salvage therapy (1)
- schizophrenia (1)
- senescence (1)
- sensory deprivation (1)
- sex‑determining region Y-box 11 (1)
- signature (1)
- single‐photon emission (1)
- size of cigarettes (1)
- skin conductance (1)
- skin involvement (1)
- sleep (1)
- slow-wave rhythms (1)
- smac mimetic (1)
- small compounds (1)
- sound analyses (1)
- sphingolipid (1)
- spirochetes (1)
- stellate reticulum (1)
- stereoselectivity (1)
- stress (1)
- stress response (1)
- stroke prevention (1)
- sulforaphane (1)
- survey (1)
- systematic review (1)
- targeted therapy (1)
- teratoma (1)
- testosterone (1)
- tetraether lipid (1)
- theranostics (1)
- therapy at the end of life (1)
- tobacco taxation (1)
- tolerance (1)
- training (1)
- treatment (1)
- trophiclevel (1)
- tumor immune escape (1)
- ubiquitin (1)
- ubiquitin coat (1)
- ubiquitin-binding zinc finger (1)
- ultra-high field MRI (1)
- vascular endothelial growth factor (1)
- vertebrates (1)
- vessel density (1)
- virological failure (1)
- waking state (1)
- wax layer (1)
- western blotting (1)
- winter survival (1)
- work ability (1)
- working conditions (1)
- xenobiotics (1)
- xenophagy (1)
- young people (1)
- μ-opioid receptor regulation (1)
Institute
- Medizin (316)
- Präsidium (11)
- Biowissenschaften (8)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Biochemie und Chemie (5)
- Pharmazie (5)
- Sonderforschungsbereiche / Forschungskollegs (4)
- Georg-Speyer-Haus (3)
- MPI für Hirnforschung (3)
- Sportwissenschaften (3)
Multidrug-resistant Gram-negative bacteria (MDR GNB) were found to colonise 60.8% (95% confidence interval: 52.3–68.9) of 143 refugee patients mainly from Syria (47), Afghanistan (29), and Somalia (14) admitted to the University Hospital Frankfurt, Germany, between June and December 2015. This percentage exceeds the prevalence of MDR GNB in resident patients four–fold. Healthcare personnel should be aware of this and the need to implement or adapt adequate infection control measures.
Repetitive transcranial magnetic stimulation (rTMS) is used as a therapeutic tool in neurology and psychiatry. While repetitive magnetic stimulation (rMS) has been shown to induce plasticity of excitatory synapses, it is unclear whether rMS can also modify structural and functional properties of inhibitory inputs. Here we employed 10-Hz rMS of entorhinohippocampal slice cultures to study plasticity of inhibitory neurotransmission on CA1 pyramidal neurons. Our experiments reveal a rMS-induced reduction in GABAergic synaptic strength (2–4 h after stimulation), which is Ca2+-dependent and accompanied by the remodelling of postsynaptic gephyrin scaffolds. Furthermore, we present evidence that 10-Hz rMS predominantly acts on dendritic, but not somatic inhibition. Consistent with this finding, a reduction in clustered gephyrin is detected in CA1 stratum radiatum of rTMS-treated anaesthetized mice. These results disclose that rTMS induces coordinated Ca2+-dependent structural and functional changes of specific inhibitory postsynapses on principal neurons.
Background: Guidelines for the control of hospital-acquired MRSA include decolonization measures to end MRSA carrier status in colonized and infected patients. Successful decolonization typically requires up to 22 days of treatment, which is longer than the average hospital length of stay (LOS). Incomplete decolonization is therefore common, with long-term MRSA carriage as a consequence. To overcome this, we developed an integrated MRSA Management (IMM) by extending MRSA decolonization to the outpatient and domestic setting. The protocol makes use of polyhexanide-based products, in view of reported qac-mediated resistance to chlorhexidine in S. aureus and MRSA.
Methods: This is a prospective, single centre, controlled, non-randomized, open-label study to evaluate the efficiency of the IMM concept. The outcome of guideline-approved decolonization during hospital stay only (control group; n = 201) was compared to the outcome following IMM treatment whereby decolonization was continued after discharge in the domestic setting or in a long-term care facility (study group; n = 99). As a secondary outcome, the effect of MRSA-status of skin alterations was assessed.
Results: The overall decolonization rate was 47 % in the IMM patient group compared to 12 % in the control group (p < 0.01). The continued treatment after hospital discharge was as effective as treatment completed during hospitalization, with microbiologically-confirmed decolonization (patients with completed regimes only) obtained with 55 % for the IMM group and 43 % for the control group (p > 0.05). For patients with skin alterations (e.g. wounds and entry sites), decolonization success was 50 % if the skin alterations were MRSA-negative at baseline, compared to 22 % success for patients entering the study with MRSA-positive skin alterations (p < 0.01).
Conclusions: The IMM strategy offers an MRSA decolonization protocol that is feasible in the domestic setting and is equally effective compared with inpatient decolonization treatment when hospital LOS is long enough to complete the treatment. Moreover, for patients with average LOS, decolonization rates obtained with IMM are significantly higher than for in-hospital treatment. IMM is a promising concept to improve decolonization rates of MRSA-carriers for patients who leave the hospital before decolonization is completed.
Acute calculus cholecystitis is a very common disease with several area of uncertainty. The World Society of Emergency Surgery developed extensive guidelines in order to cover grey areas. The diagnostic criteria, the antimicrobial therapy, the evaluation of associated common bile duct stones, the identification of “high risk” patients, the surgical timing, the type of surgery, and the alternatives to surgery are discussed. Moreover the algorithm is proposed: as soon as diagnosis is made and after the evaluation of choledocholitiasis risk, laparoscopic cholecystectomy should be offered to all patients exception of those with high risk of morbidity or mortality. These Guidelines must be considered as an adjunctive tool for decision but they are not substitute of the clinical judgement for the individual patient.
Background: Use of blood oxygenation level-dependent cardiovascular magnetic resonance (BOLD-CMR) to assess perfusion in the lower limb has been hampered by poor reproducibility and a failure to reliably detect post-revascularization improvements in patients with critical limb ischemia (CLI).
Objectives: This study sought to develop BOLD-CMR as an objective, reliable clinical tool for measuring calf muscle perfusion in patients with CLI.
Methods: The calf was imaged at 3-T in young healthy control subjects (n = 12), age-matched control subjects (n = 10), and patients with CLI (n = 34). Signal intensity time curves were generated for each muscle group and curve parameters, including signal reduction during ischemia (SRi) and gradient during reactive hyperemia (Grad). BOLD-CMR was used to assess changes in perfusion following revascularization in 12 CLI patients. Muscle biopsies (n = 28), obtained at the level of BOLD-CMR measurement and from healthy proximal muscle of patients undergoing lower limb amputation (n = 3), were analyzed for capillary-fiber ratio.
Results: There was good interuser and interscan reproducibility for Grad and SRi (all p < 0.0001). The ischemic limb had lower Grad and SRi compared with the contralateral asymptomatic limb, age-matched control subjects, and young control subjects (p < 0.001 for all comparisons). Successful revascularization resulted in improvement in Grad (p < 0.0001) and SRi (p < 0.0005). There was a significant correlation between capillary-fiber ratio (p < 0.01) in muscle biopsies from amputated limbs and Grad measured pre-operatively at the corresponding level.
Conclusions: BOLD-CMR showed promise as a reliable tool for assessing perfusion in the lower limb musculature and merits further investigation in a clinical trial.
Acetaminophen (APAP, N-acetyl-p-aminophenol, or paracetamol) overdosing is a prevalent cause of acute liver injury. While clinical disease is initiated by overt parenchymal hepatocyte necrosis in response to the analgetic, course of intoxication is substantially influenced by associated activation of innate immunity. This process is supposed to be set in motion by release of danger-associated molecular patterns (DAMPs) from dying hepatocytes and is accompanied by an inflammatory cytokine response. Murine models of APAP-induced liver injury emphasize the complex role that DAMPs and cytokines play in promoting either hepatic pathogenesis or resolution and recovery from intoxication. Whereas the function of key inflammatory cytokines is controversially discussed, a subclass of specific cytokines capable of efficiently activating the hepatocyte signal transducer and activator of transcription (STAT)-3 pathway stands out as being consistently protective in murine models of APAP intoxication. Those include foremost interleukin (IL)-6, IL-11, IL-13, and IL-22. Above all, activation of STAT3 under the influence of these cytokines has the capability to drive hepatocyte compensatory proliferation, a key principle of the regenerating liver. Herein, the role of these specific cytokines during experimental APAP-induced liver injury is highlighted and discussed in a broader perspective. In hard-to-treat or at-risk patients, standard therapy may fail and APAP intoxication can proceed toward a fatal condition. Focused administration of recombinant STAT3-activating cytokines may evolve as novel therapeutic approach under those ill-fated conditions.
Background: Among cancer care providers (CCPs), lack of knowledge constitutes an important barrier to the discussion of complementary and alternative medicine (CAM) use with patients. This study assessed CCPs’ needs and preferences regarding CAM information and training (I&T).
Methods: An online survey was completed by 209 general practitioners, 437 medical specialists, 159 oncology nurses and medical assistants, and 244 psychologists and social workers engaged in cancer care. Latent class analysis (LCA) was used to identify subgroups of individuals with distinct preference patterns regarding I&T content.
Results: CCPs prefer CAM I&T to be provided as lectures, information platforms on the internet, workshops, and e-mail newsletters. Concerning subject matters, many CCPs considered CAM therapy options for the treatment of a variety of cancer disease- and therapy-related symptoms to be very important (75%-72% of the sample); the same applies to an "overview of different CAM therapies" (74%). LCA identified 5 latent classes (LCs) of CCPs. All of them attached considerable importance to "medical indication," "potential side effects," and "tips for usage." LCs differed, however, in terms of overall importance ratings, the perceived importance of "patients’ reasons" for using specific CAM therapies, "case examples," and "scientific evidence." Notably, the 5 LCs were clearly present in all 4 occupational groups.
Conclusions: CAM I&T should provide CCPs with an overview of different CAM therapies and show how CAM might help in treating symptoms cancer patients frequently demonstrate (eg, fatigue). Moreover, I&T programs should be flexible and take into account that individual information needs vary even within the same occupational group.
Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced in septic patients and are inversely associated with disease severity. We show that serum S1P is reduced in human sepsis and in murine models of sepsis. We then investigated whether pharmacological or genetic approaches that alter serum S1P may attenuate cardiac dysfunction and whether S1P signaling might serve as a novel theragnostic tool in sepsis. Mice were challenged with lipopolysaccharide and peptidoglycan (LPS/PepG). LPS/PepG resulted in an impaired systolic contractility and reduced serum S1P. Administration of the immunomodulator FTY720 increased serum S1P, improved impaired systolic contractility and activated the phosphoinositide 3-kinase (PI3K)-pathway in the heart. Cardioprotective effects of FTY720 were abolished following administration of a S1P receptor 2 (S1P2) antagonist or a PI3K inhibitor. Sphingosine kinase-2 deficient mice had higher endogenous S1P levels and the LPS/PepG-induced impaired systolic contractility was attenuated in comparison with wild-type mice. Cardioprotective effects of FTY720 were confirmed in polymicrobial sepsis. We show here for the first time that the impaired left ventricular systolic contractility in experimental sepsis is attenuated by FTY720. Mechanistically, our results indicate that activation of S1P2 by increased serum S1P and the subsequent activation of the PI3K-Akt survival pathway significantly contributes to the observed cardioprotective effect of FTY720.
Characterization of blunt chest trauma in a long-term porcine model of severe multiple trauma
(2016)
Chest trauma has a significant relevance on outcome after severe trauma. Clinically, impaired lung function typically occurs within 72 hours after trauma. However, the underlying pathophysiological mechanisms are still not fully elucidated. Therefore, we aimed to establish an experimental long-term model to investigate physiological, morphologic and inflammatory changes, after severe trauma. Male pigs (sus scrofa) sustained severe trauma (including unilateral chest trauma, femur fracture, liver laceration and hemorrhagic shock). Additionally, non-injured animals served as sham controls. Chest trauma resulted in severe lung damage on both CT and histological analyses. Furthermore, severe inflammation with a systemic increase of IL-6 (p = 0.0305) and a local increase of IL-8 in BAL (p = 0.0009) was observed. The pO2/FiO2 ratio in trauma animals decreased over the observation period (p < 0.0001) but not in the sham group (p = 0.2967). Electrical Impedance Tomography (EIT) revealed differences between the traumatized and healthy lung (p < 0.0001). In conclusion, a clinically relevant, long-term model of blunt chest trauma with concomitant injuries has been developed. This reproducible model allows to examine local and systemic consequences of trauma and is valid for investigation of potential diagnostic or therapeutic options. In this context, EIT might represent a radiation-free method for bedside diagnostics.
Natural sounds contain information on multiple timescales, so the auditory system must analyze and integrate acoustic information on those different scales to extract behaviorally relevant information. However, this multi-scale process in the auditory system is not widely investigated in the literature, and existing models of temporal integration are mainly built upon detection or recognition tasks on a single timescale. Here we use a paradigm requiring processing on relatively ‘local’ and ‘global’ scales and provide evidence suggesting that the auditory system extracts fine-detail acoustic information using short temporal windows and uses long temporal windows to abstract global acoustic patterns. Behavioral task performance that requires processing fine-detail information does not improve with longer stimulus length, contrary to predictions of previous temporal integration models such as the multiple-looks and the spectro-temporal excitation pattern model. Moreover, the perceptual construction of putatively ‘unitary’ auditory events requires more than hundreds of milliseconds. These findings support the hypothesis of a dual-scale processing likely implemented in the auditory cortex.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle metabolism which is characterized by generalized muscle rigidity, increased body temperature, rhabdomyolysis, and severe metabolic acidosis. The underlying mechanism of MH involves excessive Ca2+ release in myotubes via the ryanodine receptor type 1 (RyR1). As RyR1 is also expressed in B–lymphocytes, this study investigated whether cellular metabolism of native B–lymphocytes was also altered in MH susceptible (MHS) individuals. A potent activator of RyR1, 4–chloro–m–cresol (4-CmC) was used to challenge native B-lymphocytes in a real–time, metabolic assay based on a pH–sensitive silicon biosensor chip. At the cellular level, a dose–dependent, phasic acidification occurred with 4–CmC. The acidification rate, an indicator of metabolic activation, was significantly higher in B–lymphocytes from MHS patients and required 3 to 5 fold lower concentrations of 4–CmC to evoke similar acidification rates to MHN. Native B–lymphocytes from MHS individuals are more sensitive to 4–CmC than those from MHN, reflecting a greater Ca2+ turnover. The acidification response, however, was less pronounced than in muscle cells, presumably reflecting the lower expression of RyR1 in B–lymphocytes.
The human sense of smell is often analyzed as being composed of three main components comprising olfactory threshold, odor discrimination and the ability to identify odors. A relevant distinction of the three components and their differential changes in distinct disorders remains a research focus. The present data-driven analysis aimed at establishing a cluster structure in the pattern of olfactory subtest results. Therefore, unsupervised machine-learning was applied onto olfactory subtest results acquired in 10,714 subjects with nine different olfactory pathologies. Using the U-matrix, Emergent Self-organizing feature maps (ESOM) identified three different clusters characterized by (i) low threshold and good discrimination and identification, (ii) very high threshold associated with absent to poor discrimination and identification ability, or (iii) medium threshold, i.e., in the mid-range of possible thresholds, associated with reduced discrimination and identification ability. Specific etiologies of olfactory (dys)function were unequally represented in the clusters (p < 2.2 · 10−16). Patients with congenital anosmia were overrepresented in the second cluster while subjects with postinfectious olfactory dysfunction belonged frequently to the third cluster. However, the clusters provided no clear separation between etiologies. Hence, the present verification of a distinct cluster structure encourages continued scientific efforts at olfactory test pattern recognition.
H2S is an important signalling molecule involved in diverse biological processes. It mediates the formation of cysteine persulfides (R-S-SH), which affect the activity of target proteins. Like thiols, persulfides show reactivity towards electrophiles and behave similarly to other cysteine modifications in a biotin switch assay. In this manuscript, we report on qPerS-SID a mass spectrometry-based method allowing the isolation of persulfide containing peptides in the mammalian proteome. With this method, we demonstrated that H2S donors differ in their efficacy to induce persulfides in HEK293 cells. Furthermore, data analysis revealed that persulfide formation affects all subcellular compartments and various cellular processes. Negatively charged amino acids appeared more frequently adjacent to cysteines forming persulfides. We confirmed our proteomic data using pyruvate kinase M2 as a model protein and showed that several cysteine residues are prone to persulfide formation finally leading to its inactivation. Taken together, the site-specific identification of persulfides on a proteome scale can help to identify target proteins involved in H2S signalling and enlightens the biology of H2S and its releasing agents.
Streptococcus pneumoniae is the most frequent cause of community-acquired pneumonia. The infection process involves bacterial cell surface receptors, which interact with host extracellular matrix components to facilitate colonization and dissemination of bacteria. Here, we investigated the role of host-derived extracellular RNA (eRNA) in the process of pneumococcal alveolar epithelial cell infection. Our study demonstrates that eRNA dose-dependently increased S. pneumoniae invasion of alveolar epithelial cells. Extracellular enolase (Eno), a plasminogen (Plg) receptor, was identified as a novel eRNA-binding protein on S. pneumoniae surface, and six Eno eRNA-binding sites including a C-terminal 15 amino acid motif containing lysine residue 434 were characterized. Although the substitution of lysine 434 for glycine (K434G) markedly diminished the binding of eRNA to Eno, the adherence to and internalization into alveolar epithelial cells of S. pneumoniae strain carrying the C-terminal lysine deletion and the mutation of internal Plg-binding motif were only marginally impaired. Accordingly, using a mass spectrometric approach, we identified seven novel eRNA-binding proteins in pneumococcal cell wall. Given the high number of eRNA-interacting proteins on pneumococci, treatment with RNase1 completely inhibited eRNA-mediated pneumococcal alveolar epithelial cell infection. Our data support further efforts to employ RNAse1 as an antimicrobial agent to combat pneumococcal infectious diseases.
Next-generation sequencing (NGS) provides unrestricted access to the genome, but it produces ‘big data’ exceeding in amount and complexity the classical analytical approaches. We introduce a bioinformatics-based classifying biomarker that uses emergent properties in genetics to separate pain patients requiring extremely high opioid doses from controls. Following precisely calculated selection of the 34 most informative markers in the OPRM1, OPRK1, OPRD1 and SIGMAR1 genes, pattern of genotypes belonging to either patient group could be derived using a k-nearest neighbor (kNN) classifier that provided a diagnostic accuracy of 80.6±4%. This outperformed alternative classifiers such as reportedly functional opioid receptor gene variants or complex biomarkers obtained via multiple regression or decision tree analysis. The accumulation of several genetic variants with only minor functional influences may result in a qualitative consequence affecting complex phenotypes, pointing at emergent properties in genetics.
ANGIOGENES : knowledge database for protein-coding and noncoding RNA genes in endothelial cells
(2016)
Increasing evidence indicates the presence of long noncoding RNAs (lncRNAs) is specific to various cell types. Although lncRNAs are speculated to be more numerous than protein-coding genes, the annotations of lncRNAs remain primitive due to the lack of well-structured schemes for their identification and description. Here, we introduce a new knowledge database “ANGIOGENES” (http://angiogenes.uni-frankfurt.de) to allow for in silico screening of protein-coding genes and lncRNAs expressed in various types of endothelial cells, which are present in all tissues. Using the latest annotations of protein-coding genes and lncRNAs, publicly-available RNA-seq data was analyzed to identify transcripts that are expressed in endothelial cells of human, mouse and zebrafish. The analyzed data were incorporated into ANGIOGENES to provide a one-stop-shop for transcriptomics data to facilitate further biological validation. ANGIOGENES is an intuitive and easy-to-use database to allow in silico screening of expressed, enriched and/or specific endothelial transcripts under various conditions. We anticipate that ANGIOGENES serves as a starting point for functional studies to elucidate the roles of protein-coding genes and lncRNAs in angiogenesis.
Obesity-associated insulin resistance is driven by inflammatory processes in response to metabolic overload. Obesity-associated inflammation can be recapitulated in cell culture by exposing macrophages to saturated fatty acids (SFA), and endoplasmic reticulum (ER) stress responses essentially contribute to pro-inflammatory signalling. AMP-activated protein kinase (AMPK) is a central metabolic regulator with established anti-inflammatory actions. Whether pharmacological AMPK activation suppresses SFA-induced inflammation in a human system is unclear. In a setting of hypoxia-potentiated inflammation induced by SFA palmitate, we found that the AMP-mimetic AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) potently suppressed upregulation of ER stress marker mRNAs and pro-inflammatory cytokines. Furthermore, AICAR inhibited macrophage ER stress responses triggered by ER-stressors thapsigargin or tunicamycin. Surprisingly, AICAR acted independent of AMPK or AICAR conversion to 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranosyl monophosphate (ZMP) while requiring intracellular uptake via the equilibrative nucleoside transporter (ENT) ENT1 or the concentrative nucleoside transporter (CNT) CNT3. AICAR did not affect the initiation of the ER stress response, but inhibited the expression of major ER stress transcriptional effectors. Furthermore, AICAR inhibited autophosphorylation of the ER stress sensor inositol-requiring enzyme 1α (IRE1α), while activating its endoribonuclease activity in vitro. Our results suggest that AMPK-independent inhibition of ER stress responses contributes to anti-inflammatory and anti-diabetic effects of AICAR.
Purpose: To determine the value of the 2D multiple-echo data image combination (MEDIC) sequence relative to the short-tau inversion recovery (STIR) sequence regarding the depiction of chondral lesions in the patellofemoral joint.
Materials and methods: During a period of 6 month patients with acute pain at the anterior aspect of the knee, joint effusion and suspected chondral lesion defect in the patellofemoral joint underwent MRI including axial MEDIC and STIR imaging. Patients with chondral lesions in the patellofemoral joint on at least one sequence were included. The MEDIC and STIR sequence were quantitatively compared regarding the patella cartilage-to-effusion contrast-to-noise ratio (CNR) and qualitatively regarding the depiction of chondral lesions independently scored by two radiologists on a 3-point scale (1 = not depicted; 2 = blurred depicted; 3 = clearly depicted) using the Wilcoxon-Mann-Whitney-Test. For the analysis of inter-observer agreement the Cohen's Weighted Kappa test was used.
Results: 30 of 58 patients (male: female, 21:9; age: 44 ± 12 yrs) revealed cartilage lesions (fissures, n = 5 including fibrillation; gaps, n = 15; delamination, n = 7; osteoarthritis, n = 3) and were included in this study. The STIR-sequence was significantly (p < 0.001) superior to the MEDIC-sequence regarding both, the patella cartilage-to-effusion CNR (mean CNR: 232 ± 61 vs. 40 ± 16) as well as the depiction of chondral lesion (mean score: 2.83 ± 0.4 vs. 1.75 ± 0.7) with substantial inter-observer agreement in the rating of both sequences (κ = 0.76–0.89).
Conclusion: For the depiction of chondral lesions in the patellofemoral joint, the axial STIR-sequence should be chosen in preference to the axial MEDIC-sequence.
Background: Computed tomography (CT) low-dose (LD) imaging is used to lower radiation exposure, especially in vascular imaging; in current literature, this is mostly on latest generation high-end CT systems.
Purpose: To evaluate the effects of reduced tube current on objective and subjective image quality of a 15-year-old 16-slice CT system for pulmonary angiography (CTPA).
Material and Methods: CTPA scans from 60 prospectively randomized patients (28 men, 32 women) were examined in this study on a 15-year-old 16-slice CT scanner system. Standard CT (SD) settings were 100 kV and 150 mAs, LD settings were 100 kV and 50 mAs. Attenuation of the pulmonary trunk, various anatomic landmarks, and image noise were quantitatively measured; contrast-to-noise ratios (CNR) and signal-to-noise ratios (SNR) were calculated. Three independent blinded radiologists subjectively rated each image series using a 5-point grading scale.
Results: CT dose index (CTDI) in the LD series was 66.46% lower compared to the SD settings (2.49 ± 0.55 mGy versus 7.42 ± 1.17 mGy). Attenuation of the pulmonary trunk showed similar results for both series (SD 409.55 ± 91.04 HU; LD 380.43 HU ± 93.11 HU; P = 0.768). Subjective image analysis showed no significant differences between SD and LD settings regarding the suitability for detection of central and peripheral PE (central SD/LD, 4.88; intra-class correlation coefficients [ICC], 0.894/4.83; ICC, 0.745; peripheral SD/LD, 4.70; ICC, 0.943/4.57; ICC, 0.919; all P > 0.4).
Conclusion: The LD protocol, on a 15-year-old CT scanner system without current high-end hardware or post-processing tools, led to a dose reduction of approximately 67% with similar subjective image quality and delineation of central and peripheral pulmonary arteries.
Aims: The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.
Methods and results: Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.
Conclusion: Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.
Clinical trial registration: ClinicalTrials.gov identifier: NCT01490814.
Summary: This retrospective database study assessed 2-year persistence with bisphosphonates or denosumab in a large German cohort of women with a first-time prescription for osteoporosis treatment. Compared with intravenous or oral bisphosphonates, 2-year persistence was 1.5–2 times higher and risk of discontinuation was significantly lower (P < 0.0001) with denosumab.
Introduction: Persistence with osteoporosis therapies is critical for fracture risk reduction. Detailed data on long-term persistence (≥2 years) with bisphosphonates and denosumab are sparse.
Methods: From the German IMS® database, we included women aged 40 years or older with a first-time prescription for bisphosphonates or denosumab between July 2010 and August 2014; patients were followed up until December 2014. The main outcome was treatment discontinuation, with a 60-day permissible gap between filled prescriptions. Two-year persistence was estimated using Kaplan–Meier survival curves, with treatment discontinuation as the failure event. Denosumab was compared with intravenous (i.v.) and oral bisphosphonates separately. Cox proportional hazard ratios (HRs) for the 2-year risk of discontinuation were calculated, with adjustment for age, physician specialty, health insurance status, and previous medication use.
Results: Two-year persistence with denosumab was significantly higher than with i.v. or oral bisphosphonates (39.8 % [n = 21,154] vs 20.9 % [i.v. ibandronate; n = 20,472] and 24.8 % [i.v. zoledronic acid; n = 3966] and 16.7–17.5 % [oral bisphosphonates; n = 114,401]; all P < 0.001). Patients receiving i.v. ibandronate, i.v. zoledronic acid, or oral bisphosphonates had a significantly increased risk of treatment discontinuation than did those receiving denosumab (HR = 1.65, 1.28, and 1.96–2.02, respectively; all P < 0.0001).
Conclusions: Two-year persistence with denosumab was 1.5–2 times higher than with i.v. or oral bisphosphonates, and risk of discontinuation was significantly lower with denosumab than with bisphosphonates. A more detailed understanding of factors affecting medication-taking behavior may improve persistence and thereby reduce rates of fracture.
More than 30% of the world's population are anemic with serious economic consequences including reduced work capacity and other obstacles to national welfare and development. Red blood cell transfusion is the mainstay to correct anemia, but it is also 1 of the top 5 overused procedures. Patient blood management (PBM) is a proactive, patient-centered, and multidisciplinary approach to manage anemia, optimize hemostasis, minimize iatrogenic blood loss, and harness tolerance to anemia. Although the World Health Organization has endorsed PBM in 2010, many hospitals still seek guidance with the implementation of PBM in clinical routine. Given the use of proven change management principles, we propose simple, cost-effective measures enabling any hospital to reduce both anemia and red blood cell transfusions in surgical and medical patients. This article provides comprehensive bundles of PBM components encompassing 107 different PBM measures, divided into 6 bundle blocks acting as a working template to develop institutions' individual PBM practices for hospitals beginning a program or trying to improve an already existing program. A stepwise selection of the most feasible measures will facilitate the implementation of PBM. In this manner, PBM represents a new quality and safety standard.
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
Purpose: Advanced Ewing sarcomas have poor prognosis. They are defined by early relapse (<24 months after diagnosis) and/or by metastasis to multiple bones or bone marrow (BM). We analyzed risk factors, toxicity and survival in advanced Ewing sarcoma patients treated with the MetaEICESS vs. EICESS92 protocols.
Design: Of 44 patients, 18 patients were enrolled into two subsequent MetaEICESS protocols between 1992 and 2014, and compared to outcomes of 26 advanced Ewing sarcoma patients treated with EICESS 1992 between 1992 and 1996. MetaEICESS 1992 consisted of induction chemotherapy, whole body imaging directed radiotherapy to the primary tumor and metastases, tandem high-dose chemotherapy and autologous rescue. In MetaEICESS 2007 this treatment was complemented by allogeneic stem cell transplantation. EICESS 1992 comprised induction chemotherapy, local therapy to the primary tumor only followed by consolidation chemotherapy.
Results: In MetaEICESS 8/18 patients survived in complete remission vs. 2/26 in EICESS 1992 (p<0.05). Survival did not differ between MetaEICESS 2007 and MetaEICESS 1992. Three MetaEICESS patients died of complications, all in MetaEICESS 1992. After exclusion of patients succumbing to treatment related complications (n=3), 7/10 patients survived without BM involvement, in contrast to 0/5 patients with BM involvement. This was confirmed in a multivariate analysis. There was no correlation between BM involvement and the number of metastases at diagnosis.
Conclusion: The MetaEICESS protocols yield long-term disease-free survival in patients with advanced Ewing sarcoma. Allogeneic stem cell transplantation was not associated with increased death of complications. Bone marrow involvement is a risk factor distinct from multiple bone metastases.
Apoptosis is deregulated in most, if not all, cancers, including hematological malignancies. Smac mimetics that antagonize Inhibitor of Apoptosis (IAP) proteins have so far largely been investigated in acute myeloid leukemia (AML) cell lines; however, little is yet known on the therapeutic potential of Smac mimetics in primary AML samples. In this study, we therefore investigated the antileukemic activity of the Smac mimetic BV6 in diagnostic samples of 67 adult AML patients and correlated the response to clinical, cytogenetic and molecular markers and gene expression profiles. Treatment with cytarabine (ara-C) was used as a standard chemotherapeutic agent. Interestingly, about half (51%) of primary AML samples are sensitive to BV6 and 21% intermediate responsive, while 28% are resistant. Notably, 69% of ara-C-resistant samples show a good to fair response to BV6. Furthermore, combination treatment with ara-C and BV6 exerts additive effects in most samples. Whole-genome gene expression profiling identifies cell death, TNFR1 and NF-κB signaling among the top pathways that are activated by BV6 in BV6-sensitive, but not in BV6-resistant cases. Furthermore, sensitivity of primary AML blasts to BV6 correlates with significantly elevated expression levels of TNF and lower levels of XIAP in diagnostic samples, as well as with NPM1 mutation. In a large set of primary AML samples, these data provide novel insights into factors regulating Smac mimetic response in AML and have important implications for the development of Smac mimetic-based therapies and related diagnostics in AML.
The multifunctional protein p21Cip1/CDKN1A (p21) is an important and universal Cdk-interacting protein. Recently, we have reported that p21 is involved in the regulation of the mitotic kinase Cdk1/cyclin B1 and critical for successful mitosis and cytokinesis. In the present work we show that S130 of p21 is phosphorylated by Cdk1/cyclin B1 during mitosis, which reduces p21’s stability and binding affinity to Cdk1/cyclin B1. Interfering with this phosphorylation results in extended mitotic duration and defective chromosome segregation, indicating that this regulation ensures proper mitotic progression. Given that p53, the major transcriptional activator of p21, is the most frequently mutated gene in human cancer and that deregulated Cdk1 associates with the development of different types of cancer, this work provides new insight into the understanding of how deregulated p21 contributes to chromosomal instability and oncogenesis.
Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells
(2016)
Polo-like kinase 1 (Plk1) has been established as one of the most promising targets for molecular anticancer intervention. In fact, various Plk1 inhibitors have been identified and characterized. While the data derived from the bench are prospective, the clinical outcomes are less encouraging by showing modest efficacy. One of the explanations for this discrepancy could be unintendedly targeting of non-malignant cells by Plk1 inhibitors. In this work, we have addressed the effect of Plk1 inhibition in adipose tissue-derived mesenchymal stem cells (ASCs). We show that both visceral and subcutaneous ASCs display monopolar spindles, reduced viability and strong apoptosis induction upon treatment with BI 2536 and BI 6727, the Plk1 kinase domain inhibitors, and with Poloxin, the regulatory Polo-box domain inhibitor. While Poloxin triggers quickly apoptosis, BI 2536 and BI 6727 result in mitotic arrest in ASCs. Importantly, survived ASCs exhibit DNA damage and a pronounced senescent phenotype. In addition, Plk1 inhibition impairs ASCs’ motility and homing ability. These results show that Plk1 inhibitors target slowly proliferating ASCs, an important population of anti-inflammation and immune modulation. The toxic effects on primary cells like ASCs could be partially responsible for the reported moderate antitumor activity in patients treated with Plk1 inhibitors.
Although the mechanistic target of rapamycin (mTOR) inhibitor, everolimus, has improved the outcome of patients with renal cell carcinoma (RCC), improvement is temporary due to the development of drug resistance. Since many patients encountering resistance turn to alternative/complementary treatment options, an investigation was initiated to evaluate whether the natural compound, sulforaphane (SFN), influences growth and invasive activity of everolimus-resistant (RCCres) compared to everolimus-sensitive (RCCpar) RCC cell lines in vitro. RCC cells were exposed to different concentrations of SFN and cell growth, cell proliferation, apoptosis, cell cycle, cell cycle regulating proteins, the mTOR-akt signaling axis, adhesion to human vascular endothelium and immobilized collagen, chemotactic activity, and influence on surface integrin receptor expression were investigated. SFN caused a significant reduction in both RCCres and RCCpar cell growth and proliferation, which correlated with an elevation in G2/M- and S-phase cells. SFN induced a marked decrease in the cell cycle activating proteins cdk1 and cyclin B and siRNA knock-down of cdk1 and cyclin B resulted in significantly diminished RCC cell growth. SFN also modulated adhesion and chemotaxis, which was associated with reduced expression of the integrin subtypes α5, α6, and β4. Distinct differences were seen in RCCres adhesion and chemotaxis (diminished by SFN) and RCCpar adhesion (enhanced by SFN) and chemotaxis (not influenced by SFN). Functional blocking of integrin subtypes demonstrated divergent action on RCC binding and invasion, depending on RCC cell sensitivity to everolimus. Therefore, SFN administration could hold potential for treating RCC patients with established resistance towards everolimus.
EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.
We assessed the prognostic value of hypoxia (carbonic anhydrase 9; CA9), vessel density (CD31), with macrophages (CD68) and B cells (CD20) that can interact and lead to immune suppression and disease progression using scanning and histological mapping of whole-mount FFPE pancreatectomy tissue sections from 141 primarily resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with surgery and adjuvant chemotherapy. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), also in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin). The median OS was 21 months after a mean follow-up of 20 months (range, 2–69 months). The median tumor surface area positive for CA9 and CD31 was 7.8% and 8.1%, respectively. Although total expression of these markers lacked prognostic value in the entire cohort, nevertheless, high tumor compartment CD68 expression correlated with worse PFS (p = 0.033) and DMFS (p = 0.047). Also, high CD31 expression predicted for worse OS (p = 0.004), PFS (p = 0.008), LPFS (p = 0.014) and DMFS (p = 0.004) in patients with moderate density stroma. High stromal and peripheral compartment CD68 expression predicted for significantly worse outcome in patients with loose and moderate stroma density, respectively. Altogether, in contrast to the current notion, hypoxia levels in PDAC appear to be comparable to other malignancies. CD31 and CD68 constitute prognostic markers in patient subgroups that vary according to tumor compartment and stromal density. Our study provides important insight on the pathophysiology of PDAC and should be exploited for future treatments.
Background: Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
Methods: HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Results: Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1–10.1), CD4 cell count 297 cells/mm3 (98–639), and HIV-RNA 5.2 log10copies/mL (4.7–5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5–10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4–23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2–54.8) versus 19.4 % (15.9–23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82–0.95; P < 0.001).
Conclusions: PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure.
Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia
(2016)
Objective: To evaluate the influence of the soluble fms-like tyrosine kinase 1/placental growth factor ratio in physicians’ decision making in pregnant women with signs and symptoms of preeclampsia in routine clinical practice.
Methods: A multicenter, prospective, open, non-interventional study enrolled pregnant women presenting with preeclampsia signs and symptoms in several European perinatal care centers. Before the soluble fms-like tyrosine kinase 1/placental growth factor ratio result was known, physicians documented intended clinical procedures using an iPad® application (data locked/time stamped). After the result was available, clinical decisions were confirmed or revised and documented. An independent adjudication committee evaluated the appropriateness of decisions based on maternal/fetal outcomes. Clinician decision making with regard to hospitalization was the primary outcome.
Results: In 16.9% of mothers (20/118) the hospitalization decision was changed after knowledge of the ratio. In 13 women (11.0%), the initial decision to hospitalize was changed to no hospitalization. In seven women (5.9%) the revised decision was hospitalization. All revised decisions were considered appropriate by the panel of adjudicators (McNemar test; p < 0.0001).
Conclusions: The use of the soluble fms-like tyrosine kinase 1/placental growth factor test influenced clinical decision making towards appropriate hospitalization in a considerable proportion of women with suspected preeclampsia. This is the first study to demonstrate the impact of angiogenic biomarkers on decision making in a routine clinical practice.
Background: Hemodynamic instability is frequent and outcome-relevant in critical illness. The understanding of complex hemodynamic disturbances and their monitoring and management plays an important role in treatment of intensive care patients. An increasing number of treatment recommendations and guidelines in intensive care medicine emphasize hemodynamic goals, which go beyond the measurement of blood pressures. Yet, it is not known to which extent the infrastructural prerequisites for extended hemodynamic monitoring are given in intensive care units (ICUs) and how hemodynamic management is performed in clinical practice. Further, it is still unclear which factors trigger the use of extended hemodynamic monitoring.
Methods: In this multicenter, 1-day (November 7, 2013, and the preceding 24 h) cross-sectional study, we retrieved data on patient monitoring from ICUs in Germany, Austria, and Switzerland by means of a web-based case report form. One hundred and sixty-one intensive care units contributed detailed information on availability of hemodynamic monitoring. In addition, detailed information on hemodynamic monitoring of 1789 patients that were treated on due date was collected, and independent factors triggering the use of extended hemodynamic monitoring were identified by multivariate analysis.
Results: Besides basic monitoring with electrocardiography (ECG), pulse oximetry, and blood pressure monitoring, the majority of patients received invasive arterial (77.9 %) and central venous catheterization (55.2 %). All over, additional extended hemodynamic monitoring for assessment of cardiac output was only performed in 12.3 % of patients, while echocardiographic examination was used in only 1.9 %. The strongest independent predictors for the use of extended hemodynamic monitoring of any kind were mechanical ventilation, the need for catecholamine therapy, and treatment backed by protocols. In 71.6 % of patients in whom extended hemodynamic monitoring was added during the study period, this extension led to changes in treatment.
Conclusions: Extended hemodynamic monitoring, which goes beyond the measurement of blood pressures, to date plays a minor role in the surveillance of critically ill patients in German, Austrian, and Swiss ICUs. This includes also consensus-based recommended diagnostic and monitoring applications, such as echocardiography and cardiac output monitoring. Mechanical ventilation, the use of catecholamines, and treatment backed by protocol could be identified as factors independently associated with higher use of extended hemodynamic monitoring.
Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage induction and Mcl-1 depletion were suggested instead. Here we investigated the efficacy and mechanism of action of YM155 in neuroblastoma cells with acquired drug resistance. The efficacy of YM155 was determined in neuroblastoma cell lines and their sublines with acquired resistance to clinically relevant drugs. Survivin levels, Mcl-1 levels, and DNA damage formation were determined in response to YM155. RNAi-mediated depletion of survivin, Mcl-1, and p53 was performed to investigate their roles during YM155 treatment. Clinical YM155 concentrations affected the viability of drug-resistant neuroblastoma cells through survivin depletion and p53 activation. MDM2 inhibitor-induced p53 activation further enhanced YM155 activity. Loss of p53 function generally affected anti-neuroblastoma approaches targeting survivin. Upregulation of ABCB1 (causes YM155 efflux) and downregulation of SLC35F2 (causes YM155 uptake) mediated YM155-specific resistance. YM155-adapted cells displayed increased ABCB1 levels, decreased SLC35F2 levels, and a p53 mutation. YM155-adapted neuroblastoma cells were also characterized by decreased sensitivity to RNAi-mediated survivin depletion, further confirming survivin as a critical YM155 target in neuroblastoma. In conclusion, YM155 targets survivin in neuroblastoma. Furthermore, survivin is a promising therapeutic target for p53 wild-type neuroblastomas after resistance acquisition (neuroblastomas are rarely p53-mutated), potentially in combination with p53 activators. In addition, we show that the adaptation of cancer cells to molecular-targeted anticancer drugs is an effective strategy to elucidate a drug’s mechanism of action.
Background: Community acquired viruses (CRVs) may cause severe disease in cancer patients. Thus, efforts should be made to diagnose CRV rapidly and manage CRV infections accordingly.
Methods: A panel of 18 clinicians from the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology have convened to assess the available literature and provide recommendations on the management of CRV infections including influenza, respiratory syncytial virus, parainfluenza virus, human metapneumovirus and adenovirus.
Results: CRV infections in cancer patients may lead to pneumonia in approximately 30% of the cases, with an associated mortality of around 25%. For diagnosis of a CRV infection, combined nasal/throat swabs or washes/aspirates give the best results and nucleic acid amplification based-techniques (NAT) should be used to detect the pathogen. Hand hygiene, contact isolation and face masks have been shown to be of benefit as general infection management. Causal treatment can be given for influenza, using a neuraminidase inhibitor, and respiratory syncytial virus, using ribavirin in addition to intravenous immunoglobulins. Ribavirin has also been used to treat parainfluenza virus and human metapneumovirus, but data are inconclusive in this setting. Cidofovir is used to treat adenovirus pneumonitis.
Conclusions: CRV infections may pose a vital threat to patients with underlying malignancy. This guideline provides information on diagnosis and treatment to improve the outcome.
Background: Shortening duration of peginterferon-based HCV treatment reduces associated burden for patients. Primary objectives of this study were to assess the efficacy against the minimally acceptable response rate 12 weeks post-treatment (SVR12) and safety of simeprevir plus PR in treatment-naïve HCV GT1 patients treated for 12 weeks. Additional objectives included the investigation of potential associations of rapid viral response and baseline factors with SVR12.
Methods: In this Phase III, open-label study in treatment-naïve HCV GT1 patients with F0–F2 fibrosis, patients with HCV-RNA <25 IU/mL (detectable/undetectable) at Week 2, and undetectable HCV-RNA at Weeks 4 and 8, stopped all treatment at Week 12. All other patients continued PR for a further 12 weeks. Baseline factors significantly associated with SVR12 were identified through logistic regression.
Results: Of 163 patients who participated in the study, 123 (75%) qualified for 12-week treatment; of these, 81 (66%) achieved SVR12. Baseline factors positively associated with SVR12 rates in patients receiving the 12-week regimen were: IL28B CC genotype: (94% SVR12); HCV RNA ≤800,000 IU/mL (82%); F0–F1 fibrosis (74%). Among all 163 patients, 94% experienced ≥1 adverse event (AE), 4% a serious AE, and 2.5% discontinued due to an AE. Reduced impairment in patient-reported outcomes was observed in the 12-week vs >12-week regimen.
Conclusions: Overall SVR12 rate (66%) was below the target of 80%, indicating that shortening of treatment with simeprevir plus PR to 12 weeks based on very early response is not effective. However, baseline factors associated with higher SVR12 rates were identified. Therefore, while Week 2 response alone is insufficient to predict efficacy, GT1 patients with favourable baseline factors may benefit from a shortened simeprevir plus PR regimen.
Trial Registration: ClinicalTrials.gov NCT01846832
Background: Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide. Growing evidence indicates that tumor-initiating cells (TICs) are responsible for tumor growth and progression. Conventional chemotherapeutics do not sufficiently eliminate TICs, leading to tumor relapse. We aimed to gain insight into TIC biology by comparing the transcriptome of primary TIC cultures and their normal stem cell counterparts to uncover expression differences.
Methods: We established colonosphere cultures derived from the resection of paired specimens of primary tumor and normal mucosa in patients with CRC. These colonospheres, enriched for TICs, were used for differential transcriptome analyses to detect new targets for a TIC-directed therapy. Effects of target inhibition on CRC cells were studied in vitro and in vivo.
Results: Pathway analysis of the regulated genes showed enrichment of genes central to PI3K/AKT and Wnt-signaling. We identified CD133 as a marker for a more aggressive CRC subpopulation enriched with TICs in SW480 CRC cells in an in vivo cancer model. Treatment of CRC cells with the selective AKT inhibitor MK-2206 caused a decrease in cell proliferation, particularly in the TIC fraction, resulting in a significant reduction of the stemness capacity to form colonospheres in vitro and to initiate tumor formation in vivo. Consequently, MK-2206 treatment of mice with established xenograft tumors exhibited a significant deceleration of tumor progression. Primary patient-derived tumorsphere growth was significantly inhibited by MK-2206.
Conclusion: This study reveals that AKT signaling is critical for TIC proliferation and can be efficiently targeted by MK-2206 representing a preclinical therapeutic strategy to repress colorectal TICs.
Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for the cohort without IT and .69 ± .10 for IT patients. Incidences of relapse (CIR) and treatment-related mortality (CITRM) were equally distributed between both cohorts (without IT: 3-year CIR, .21 ± .05, 3-year CITRM, .10 ± .04; IT patients: 3-year CIR, .18 ± .09, 3-year CITRM .13 ± .07). Accordingly, 3-year EFS and 3-year CIR were similar in CC and MC patients with IT, whereas MC patients without IT experienced relapse. IT was neither associated with an enhanced immune recovery nor an increased risk for acute graft-versus-host disease. Relapse prevention by IT in patients at risk may lead to the same favorable outcome as found in CC and MRD-negative-patients. This underlines the importance of excellent MRD and chimerism monitoring after transplantation as the basis for IT to improve survival in childhood ALL.
Infant acute leukemia still has a poor prognosis, and allogeneic hematopoietic stem cell transplantation is indicated in selected patients. Umbilical cord blood (UCB) is an attractive cell source for this population because of the low risk of chronic graft-versus-host disease (GVHD), the strong graft-versus-leukemia effect, and prompt donor availability. This retrospective, registry-based study reported UCB transplantation (UCBT) outcomes in 252 children with acute lymphoblastic leukemia (ALL; n = 157) or acute myelogenous leukemia (AML; n = 95) diagnosed before 1 year of age who received a single-unit UCBT after myeloablative conditioning between 1996 and 2012 in European Society for Blood and Marrow Transplantation centers. Median age at UCBT was 1.1 years, and median follow-up was 42 months. Most patients (57%) received a graft with 1 HLA disparity and were transplanted in first complete remission (CR; 55%). Cumulative incidence function (CIF) of day 100 acute GVHD (grades II to IV) was 40% ± 3% and of 4-year chronic GVHD was 13% ± 2%. CIF of 1-year transplant-related mortality was 23% ± 3% and of 4-year relapse was 27% ± 3%. Leukemia-free-survival (LFS) at 4 years was 50% ± 3%; it was 40% and 66% for those transplanted for ALL and AML, respectively (P = .001). LFS was better for patients transplanted in first CR, regardless of diagnosis. In multivariate model, diagnosis of ALL (P = .001), advanced disease status at UCBT (<.001), age at diagnosis younger than 3 months (P = .012), and date of transplant before 2004 were independently associated with worse LFS. UCBT is a suitable option for patients diagnosed with infant acute leukemia who achieve CR. In this cohort, patients with AML had better survival than those with ALL.
Natural Killer (NK) cells are active against Aspergillus fumigatus, which in turn is able to impair the host defense. Unfortunately, little is known on the mutual interaction of NK cells and A. fumigatus. We coincubated human NK cells with A. fumigatus hyphae and assessed the gene expression and protein concentration of selected molecules. We found that A. fumigatus up-regulates the gene expression of pro-inflammatory molecules in NK cells, but inhibited the release of these molecules resulting in intracellular accumulation and limited extracellular availability. A. fumigatus down-regulatedmRNA levels of perforin in NK cells, but increased its intra- and extracellular protein concentration. The gene expression of stress related molecules of A. fumigatus such as heat shock protein hsp90 was up-regulated by human NK cells. Our data characterize for the first time the immunosuppressive effect of A. fumigatus on NK cells and may help to develop new therapeutic antifungal strategies.
We have recently shown that caspase-8 is a new substrate of Polo-like kinase 3 (Plk3) that phosphorylates the protein on residue T273 thereby promoting its pro-apoptotic function. In the present study we aimed to investigate the clinical relevance of Plk3 expression and phosphorylation of caspase-8 at T273 in patients with anal squamous cell carcinoma (SSC) treated with 5-fluorouracil and mitomycin C-based chemoradiotherapy (CRT). Immunohistochemical detection of the markers was performed in pretreatment biopsy specimens of 95 patients and was correlated with clinical/histopathologic characteristics including HPV-16 virus load/p16INK4a expression and cumulative incidence of local and distant failure, cancer specific survival (CSS), and overall survival (OS). We observed significant positive correlations between Plk3 expression, pT273 caspase-8 signal, and levels of HPV-16 virus DNA load/p16INK4a detection. Patients with high scores of Plk3 and pT273 caspase-8 showed increased local control (p = 0.011; p = 0.001), increased CSS (p = 0.011; p = 0.013) and OS (p = 0.024; p = 0.001), while the levels of pT273 caspase-8 were significantly associated (p = 0.033) with distant metastases. In multivariate analyses Plk3 expression remained significant for local failure (p = 0.018), CSS (p = 0.016) and OS (p = 0.023). Moreover, a combined HPV16 DNA load and Plk3 or pT273 caspase-8 variable revealed a significant correlation to decreased local failure (p = 0.001; p = 0.009), increased CSS (p = 0.016; p = 0.023) and OS (p = 0.003; p = 0.003). In conclusion these data indicate that elevated levels of Plk3 and pT273 caspase-8 are correlated with favorable clinical outcome in patients with anal SCC treated with concomitant CRT.
Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion
(2016)
Renal cell carcinoma (RCC) escapes immune recognition. To elaborate the escape strategy the influence of RCC cells on endothelial receptor expression and endothelial leukocyte adhesion was evaluated. Human umbilical vein endothelial cells (HUVEC) were co-cultured with the RCC cell line, Caki-1, with and without tumor necrosis factor (TNF)-alpha. Intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), endothelial (E)-selectin, standard and variants (V) of CD44 were then analysed in HUVEC, using flow cytometry and Western blot analysis. To determine which components are responsible for HUVEC-Caki-1 interaction causing receptor alteration, Caki-1 membrane fragments versus cell culture supernatant were applied to HUVECS. Adhesion of peripheral blood lymphocytes (PBL) and polymorphonuclear neutrophils (PMN) to endothelium was evaluated by co-culture adhesion assays. Relevance of endothelial receptor expression for adhesion to endothelium was determined by receptor blockage. Co-culture of RCC and HUVECs resulted in a significant increase in endothelial ICAM-1, VCAM-1, E-selectin, CD44 V3 and V7 expression. Previous stimulation of HUVECs with TNF-alpha and co-cultivation with Caki-1 resulted in further elevation of endothelial CD44 V3 and V7 expression, whereas ICAM-1, VCAM-1 and E-selectin expression were significantly diminished. Since Caki-1 membrane fragments also caused these alterations, but cell culture supernatant did not, cell-cell contact may be responsible for this process. Blocking ICAM-1, VCAM-1, E-selectin or CD44 with respective antibodies led to a significant decrease in PBL and PMN adhesion to endothelium. Thus, exposing HUVEC to Caki-1 results in significant alteration of endothelial receptor expression and subsequent endothelial attachment of PBL and PMN.
Purpose: Few individuals that are latently infected with M. tuberculosis latent tuberculosis infection(LTBI) progress to active disease. We investigated risk factors for LTBI and active pulmonary tuberculosis (PTB) in Germany.
Methods: Healthy household contacts (HHCs), health care workers (HCWs) exposed to M. tuberculosis and PTB patients were recruited at 18 German centres. Interferon-γ release assay (IGRA) testing was performed. LTBI risk factors were evaluated by comparing IGRA-positive with IGRA-negative contacts. Risk factors for tuberculosis were evaluated by comparing PTB patients with HHCs.
Results: From 2008–2014, 603 HHCs, 295 HCWs and 856 PTBs were recruited. LTBI was found in 34.5% of HHCs and in 38.9% of HCWs. In HCWs, care for coughing patients (p = 0.02) and longstanding nursing occupation (p = 0.04) were associated with LTBI. In HHCs, predictors for LTBI were a diseased partner (odds ratio 4.39), sexual contact to a diseased partner and substance dependency (all p < 0.001). PTB was associated with male sex, low body weight (p < 0.0001), alcoholism (15.0 vs 5.9%; p < 0.0001), glucocorticoid therapy (7.2 vs 2.0%; p = 0.004) and diabetes (7.8 vs. 4.0%; p = 0.04). No contact developed active tuberculosis within 2 years follow-up.
Conclusions: Positive IGRA responses are frequent among exposed HHCs and HCWs in Germany and are poor predictors for the development of active tuberculosis.
Measuring NADPH oxidase (Nox)-derived reactive oxygen species (ROS) in living tissues and cells is a constant challenge. All probes available display limitations regarding sensitivity, specificity or demand highly specialized detection techniques. In search for a presumably easy, versatile, sensitive and specific technique, numerous studies have used NADPH-stimulated assays in membrane fractions which have been suggested to reflect Nox activity. However, we previously found an unaltered activity with these assays in triple Nox knockout mouse (Nox1-Nox2-Nox4-/-) tissue and cells compared to wild type. Moreover, the high ROS production of intact cells overexpressing Nox enzymes could not be recapitulated in NADPH-stimulated membrane assays. Thus, the signal obtained in these assays has to derive from a source other than NADPH oxidases. Using a combination of native protein electrophoresis, NADPH-stimulated assays and mass spectrometry, mitochondrial proteins and cytochrome P450 were identified as possible source of the assay signal. Cells lacking functional mitochondrial complexes, however, displayed a normal activity in NADPH-stimulated membrane assays suggesting that mitochondrial oxidoreductases are unlikely sources of the signal. Microsomes overexpressing P450 reductase, cytochromes b5 and P450 generated a NADPH-dependent signal in assays utilizing lucigenin, L-012 and dihydroethidium (DHE). Knockout of the cytochrome P450 reductase by CRISPR/Cas9 technology (POR-/-) in HEK293 cells overexpressing Nox4 or Nox5 did not interfere with ROS production in intact cells. However, POR-/- abolished the signal in NADPH-stimulated assays using membrane fractions from the very same cells. Moreover, membranes of rat smooth muscle cells treated with angiotensin II showed an increased NADPH-dependent signal with lucigenin which was abolished by the knockout of POR but not by knockout of p22phox. In conclusion: the cytochrome P450 system accounts for the majority of the signal of Nox activity chemiluminescence based assays.
Infections of the central nervous system (CNS) are infrequently diagnosed in immunocompetent patients, but they do occur in a significant proportion of patients with hematological disorders. In particular, patients undergoing allogeneic hematopoietic stem-cell transplantation carry a high risk for CNS infections of up to 15%. Fungi and Toxoplasma gondii are the predominant causative agents. The diagnosis of CNS infections is based on neuroimaging, cerebrospinal fluid examination and biopsy of suspicious lesions in selected patients. However, identification of CNS infections in immunocompromised patients could represent a major challenge since metabolic disturbances, side-effects of antineoplastic or immunosuppressive drugs and CNS involvement of the underlying hematological disorder may mimic symptoms of a CNS infection. The prognosis of CNS infections is generally poor in these patients, albeit the introduction of novel substances (e.g. voriconazole) has improved the outcome in distinct patient subgroups. This guideline has been developed by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) with the contribution of a panel of 14 experts certified in internal medicine, hematology/oncology, infectious diseases, intensive care, neurology and neuroradiology. Grades of recommendation and levels of evidence were categorized by using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases.
Bone losses are common as a consequence of unloading and also in patients with chronic obstructive pulmonary disease (COPD). Although hypoxia has been implicated as an important factor to drive bone loss, its interaction with unloading remains unresolved. The objective therefore was to assess whether human bone loss caused by unloading could be aggravated by chronic hypoxia.
In a cross-over designed study, 14 healthy young men underwent 21-day interventions of bed rest in normoxia (NBR), bed rest in hypoxia (HBR), and hypoxic ambulatory confinement (HAmb). Hypoxic conditions were equivalent to 4000 m altitude. Bone metabolism (NTX, P1NP, sclerostin, DKK1) and phospho-calcic homeostasis (calcium and phosphate serum levels and urinary excretion, PTH) were assessed from regular blood samples and 24-hour urine collections, and tibia and femur bone mineral content was assessed by peripheral quantitative computed tomography (pQCT).
Urinary NTX excretion increased (P < 0.001) to a similar extent in NBR and HBR (P = 0.69) and P1NP serum levels decreased (P = 0.0035) with likewise no difference between NBR and HBR (P = 0.88). Serum total calcium was increased during bed rest by 0.059 (day D05, SE 0.05 mM) to 0.091 mM (day D21, P < 0.001), with no additional effect by hypoxia during bed rest (P = 0.199). HAmb led, at least temporally, to increased total serum calcium, to reduced serum phosphate, and to reduced phosphate and calcium excretion.
In conclusion, hypoxia did not aggravate bed rest-induced bone resorption, but led to changes in phospho-calcic homeostasis likely caused by hyperventilation. Whether hyperventilation could have mitigated the effects of hypoxia in this study remains to be established.
Latent transforming growth factor beta binding protein 4 (LTBP4) belongs to the fibrillin/LTBP family of proteins and plays an important role as a structural component of extracellular matrix (ECM) and local regulator of TGFβ signaling. We have previously reported that Ltbp4S knock out mice (Ltbp4S −/−) develop centrilobular emphysema reminiscent of late stage COPD, which could be partially rescued by inactivating the antioxidant protein Sestrin 2 (Sesn2). More recent studies showed that Sesn2 knock out mice upregulate Pdgfrβ-controlled alveolar maintenance programs that protect against cigarette smoke induced pulmonary emphysema. Based on this, we hypothesized that the emphysema of Ltbp4S −/− mice is primarily caused by defective Pdgfrβ signaling. Here we show that LTBP4 induces Pdgfrβ signaling by inhibiting the antioxidant Nrf2/Keap1 pathway in a TGFβ-dependent manner. Overall, our data identified Ltbp4 as a major player in lung remodeling and injury repair.
Sequence type 131 (ST131) is one of the predominant Escherichia coli lineages among extraintestinal pathogenic E. coli (ExPEC) that causes a variety of diseases in humans and animals and frequently shows multidrug resistance. Here, we report the first genome sequence of an ST131-ExPEC strain from poultry carrying the plasmid-encoded colistin resistance gene mcr-1.
Background: Cancer screening participation rates in Germany differ depending on patients’ gender. International studies have found that patient–physician gender concordance fosters recommendation and conducting of cancer screening, and especially cancer screening for women.
Objectives: We aimed to ascertain whether gender concordance influences general practitioners' (GPs’) rating of the usefulness of cancer screening, as well as their recommendations and readiness to conduct cancer screening in general practice in Germany.
Methods: For an exploratory cross-sectional survey, 500 randomly selected GPs from all over Germany were asked to fill in a questionnaire on cancer screening in general practice between March and June 2015. We asked them to rate the usefulness of each cancer screening examination, how frequently they recommended and conducted them and whether they viewed GPs or specialists as responsible for carrying them out. We used multiple logistic regression to analyse gender effect size by calculating odds ratios.
Results: Our study sample consisted of 139 GPs of which 65% were male. Male and female GPs did not differ significantly in their rating of the general usefulness of any of the specified cancer screening examinations. Male GPs were 2.9 to 6.8 times as likely to consider GPs responsible for recommending and conducting PSA testing and digital rectal examinations and were 3.7 to 7.9 times as likely to recommend and conduct these examinations on a regular basis.
Conclusion: Patient–physician gender concordance made it more likely that male-specific cancer screenings would be recommended and conducted, but not female-specific screenings.